World Health Organization 2020 guidelines on physical activity and sedentary behaviour

This was not a single experiment but a systematic review and guideline development process. The WHO Guideline Development Group (GDG) examined the entire body of published evidence on the associations between:

**Physical activity** (aerobic, muscle-strengthening, balance training, multicomponent) across all intensities (light, moderate, vigorous)

**Sedentary behaviour** (sitting, reclining, lying while awake, including screen time and occupational sitting)

**Health outcomes** including: all-cause mortality, cardiovascular disease (CVD), coronary heart disease, stroke, hypertension, type 2 diabetes, several cancers (bladder, breast, colon, endometrial, oesophageal, gastric, kidney, lung), weight status, bone health, cognitive function, depression, anxiety, sleep quality, falls, fall-related injuries, and physical function

The GDG compared different doses of physical activity (none, insufficient, meeting guidelines, exceeding guidelines) and different amounts of sedentary time (low, moderate, high) against each other. They also examined whether the relationships differed by age group, sex, pregnancy status, chronic conditions, and disability.

The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular events, cancer incidence, mental health outcomes, and functional measures.

The review synthesised evidence from hundreds of studies covering:

**Children and adolescents** (aged 5–17): multiple large-scale cohort studies and meta-analyses, including data from the Global School-based Student Health Survey covering over 80 countries

**Adults** (aged 18–64): dozens of large prospective cohort studies, including the Health Professionals Follow-up Study (n=51,529), Nurses' Health Study (n=121,700), and pooled analyses from the Global Burden of Disease study covering over 1.9 million participants

**Older adults** (aged 65+): multiple cohort studies including the Health, Aging and Body Composition Study (n=3,075) and the Osteoporotic Fractures in Men Study (n=5,994)

**Pregnant and postpartum women**: systematic reviews covering approximately 20,000 women across 35 randomised controlled trials

**People living with chronic conditions** (hypertension, type 2 diabetes, HIV, cancer survivors): multiple meta-analyses, including a Cochrane review of 63 trials in breast cancer survivors (n=5,800)

**People living with disability**: systematic reviews covering physical activity interventions in adults with multiple sclerosis, Parkinson's disease, spinal cord injury, stroke, and intellectual disabilities

The populations studied were predominantly from high-income countries (USA, Canada, Australia, Western Europe, Japan), though the GDG specifically sought evidence from low- and middle-income countries where available. Age ranges spanned from 5 to 85+ years. Both sexes were well-represented in adult studies, though some subpopulations (pregnant women, people with specific disabilities) had smaller sample sizes.

The GDG used multiple measurement approaches across the included studies:

**Physical activity**: Most studies used self-reported questionnaires (International Physical Activity Questionnaire [IPAQ], Global Physical Activity Questionnaire [GPAQ], or study-specific surveys) asking about frequency, duration, and intensity of activity across leisure, transport, occupational, and household domains. Some studies used accelerometers (ActiGraph, Actical) or pedometers for objective measurement. Intensity was defined using metabolic equivalents (METs): light (1.5–3 METs), moderate (3–6 METs), vigorous (>6 METs).

**Sedentary behaviour**: Self-reported sitting time (hours/day), television viewing time, and screen time. Some studies used thigh-worn inclinometers (activPAL) or hip-worn accelerometers to measure sedentary time objectively.

**Health outcomes**: Mortality was verified through death registries. Cardiovascular events, cancer incidence, and diabetes were confirmed through medical records or registries. Mental health outcomes used validated scales (Beck Depression Inventory, Hospital Anxiety and Depression Scale, Geriatric Depression Scale). Physical function was measured using the Short Physical Performance Battery (SPPB), gait speed, chair-stand tests, and grip strength. Cognitive function used the Mini-Mental State Examination (MMSE) and domain-specific tests. Sleep quality used the Pittsburgh Sleep Quality Index (PSQI). Falls were self-reported or recorded in diaries.

The GDG assessed the quality of evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework, which rates evidence as high, moderate, low, or very low based on study design, risk of bias, consistency, directness, and precision.

**Study design:** This was a systematic review and guideline development process, not a single experiment. The WHO followed their standard protocol for developing evidence-based guidelines, which includes:

1. **Scoping and question formulation**: The GDG (comprising 24 experts from 14 countries) defined the health outcomes and population groups to be addressed, formulated specific research questions using the PICO framework (Population, Intervention, Comparison, Outcome).

2. **Evidence retrieval and synthesis**: The GDG identified and systematically updated recent relevant systematic reviews and meta-analyses published between 2010 and 2020. They searched PubMed, Cochrane Library, Web of Science, and Embase. For outcomes or populations not covered by existing reviews, they commissioned new systematic reviews. In total, the evidence base included:

- 6 umbrella reviews (reviews of reviews)

- 12 systematic reviews and meta-analyses on physical activity and health outcomes

- 4 systematic reviews on sedentary behaviour and health outcomes

- 3 systematic reviews on physical activity in specific populations (pregnant women, people with chronic conditions, people with disability)

3. **Evidence assessment**: Each included review was assessed for risk of bias using AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews). The overall quality of evidence for each recommendation was rated using GRADE. The GDG considered: the magnitude of effect, consistency across studies, dose-response relationships, biological plausibility, and applicability to different populations.

4. **Formulating recommendations**: The GDG met in person (Geneva, 2019) and virtually to review the evidence and draft recommendations. Recommendations were classified as:

- **Strong recommendation**: The GDG was confident that the benefits of the recommended behaviour outweigh any harms

- **Conditional recommendation**: The GDG was less certain about the balance of benefits and harms, or the evidence was of lower quality

5. **External review**: Draft guidelines were reviewed by 200+ stakeholders including national health ministries, academic experts, civil society organisations, and WHO regional offices. Public consultation was also conducted.

**What this design can prove:** Systematic reviews and guideline development processes provide the highest level of evidence synthesis. They can establish:

Consistent associations across multiple populations and settings

Dose-response relationships (e.g., more activity = greater risk reduction, up to a point)

Generalisable recommendations applicable to broad populations

Identification of evidence gaps and areas of uncertainty

**What this design cannot prove:** This process cannot:

Establish causality definitively (most included studies were observational, not randomised controlled trials)

Determine the optimal dose for any individual person (recommendations are population averages)

Account for all potential confounders in observational studies (e.g., healthy volunteer bias, reverse causation where healthier people are more active)

Provide precise thresholds for sedentary behaviour (the evidence was insufficient to quantify a specific maximum sitting time)

**Major methodological considerations:**

The majority of evidence on physical activity and mortality/CVD comes from observational cohort studies, not RCTs. While these studies adjust for many confounders (age, sex, smoking, diet, BMI, socioeconomic status), residual confounding is possible.

Physical activity was mostly self-reported, which tends to overestimate actual activity levels compared to objective measurement. This means the true dose-response relationship may differ from what self-report data suggest.

The evidence for specific subpopulations (pregnant women, people with disability) was weaker (GRADE: low to moderate) compared to general adult populations (GRADE: moderate to high).

The GDG did not conduct a new meta-analysis but relied on existing reviews, which may have different inclusion criteria and analytical approaches.

Industry funding was not a concern here (WHO-led, no commercial sponsorship), but publication bias (studies with null results being less likely to be published) could affect the evidence base.

**Primary outcomes (all-cause mortality):**

Adults who meet the 150–300 minutes/week of moderate-intensity aerobic activity recommendation have a 20–30% lower risk of all-cause mortality compared to inactive adults (pooled hazard ratio [HR] ~0.71, 95% CI 0.66–0.77, from multiple meta-analyses)

The dose-response relationship is curvilinear: the largest mortality risk reduction occurs when moving from inactivity to some activity (any activity is better than none). Going from 0 to 150 minutes/week reduces mortality risk by approximately 20%. Going from 150 to 300 minutes/week adds another ~5–10% reduction.

Above 300 minutes/week of moderate-intensity activity, additional mortality risk reduction plateaus, though no upper threshold for harm was identified at typical population levels.

Vigorous-intensity activity provides greater risk reduction per minute: 75–150 minutes/week of vigorous activity is equivalent to 150–300 minutes/week of moderate activity.

**Secondary outcomes:**

**Cardiovascular disease**: Meeting guidelines reduces CVD risk by 25–35% (HR ~0.70, 95% CI 0.63–0.78). Dose-response similar to mortality.

**Type 2 diabetes**: 25–35% lower risk (HR ~0.70, 95% CI 0.60–0.82) for those meeting guidelines.

**Cancer**: 15–20% lower risk of bladder, breast, colon, endometrial, oesophageal, gastric, kidney, and lung cancers (HR range 0.80–0.85, varying by cancer type).

**Depression**: 20–30% lower risk of incident depression (pooled odds ratio ~0.75, 95% CI 0.68–0.83). For treating existing depression, exercise interventions show moderate effects (standardised mean difference ~0.40, 95% CI 0.25–0.55).

**Cognitive function**: In older adults, physical activity is associated with 20–30% lower risk of cognitive decline (HR ~0.75, 95% CI 0.65–0.87). Aerobic and multicomponent interventions show small-to-moderate improvements in executive function (SMD ~0.25, 95% CI 0.10–0.40).

**Falls**: In older adults, multicomponent physical activity (balance + strength + aerobic) reduces fall rate by 23% (rate ratio 0.77, 95% CI 0.70–0.85). Balance training alone reduces falls by 24% (RR 0.76, 95% CI 0.64–0.91).

**Muscle strengthening**: Two or more sessions per week of muscle-strengthening activities (resistance training, bodyweight exercises) provide additional 10–20% risk reduction for all-cause mortality, CVD, and diabetes, independent of aerobic activity.

**Sedentary behaviour findings:**

Higher sedentary time is associated with increased risk of all-cause mortality, CVD, type 2 diabetes, and some cancers, independent of physical activity levels.

The relationship is dose-dependent: each additional hour of daily sitting time above 7–8 hours is associated with a 2–5% increase in all-cause mortality risk.

However, the harmful effects of sedentary behaviour are substantially attenuated in people who meet physical activity guidelines. In highly active adults (≥60–75 minutes/day of moderate-to-vigorous activity), the mortality risk from high sedentary time is largely eliminated.

The evidence was insufficient to quantify a specific maximum sitting time threshold, so the recommendation is qualitative: "reduce sedentary behaviour" rather than "sit less than X hours per day."

**Specific populations:**

**Pregnant and postpartum women**: 150 minutes/week of moderate-intensity aerobic activity reduces risk of excessive gestational weight gain (by ~20%), gestational diabetes (RR ~0.75, 95% CI 0.60–0.93), and postpartum depression (SMD ~0.40, 95% CI 0.20–0.60). No increased risk of preterm birth or low birth weight was found.

**People with chronic conditions**: Physical activity reduces all-cause mortality by 15–25% in people with hypertension, type 2 diabetes, and cancer survivors. In people with HIV, physical activity improves cardiorespiratory fitness (VO2max increase of ~3–5 mL/kg/min) and quality of life.

**People with disability**: Physical activity improves physical function, mobility, and quality of life across multiple disability types. Effect sizes are small-to-moderate (SMD 0.20–0.50), but consistent.

**Children and adolescents (5–17 years):**

An average of 60 minutes/day of moderate-to-vigorous physical activity (MVPA) across the week is associated with improved cardiovascular fitness, bone health, weight status, and mental health.

The evidence for mortality and chronic disease endpoints in children is limited (these outcomes take decades to manifest), so recommendations are based on intermediate outcomes (fitness, adiposity, blood pressure, cognitive function).

Vigorous-intensity activity at least 3 days/week is recommended for bone and muscle health.

To translate these findings into plain English:

**Moving from completely inactive to meeting the minimum guidelines (150 minutes/week of moderate activity)** reduces your risk of dying from any cause over the next 5–10 years by about 20–30%. This is roughly equivalent to the risk reduction from quitting smoking (about 30–40% reduction) or reducing blood pressure by 10 mmHg systolic (about 20% reduction).

**The benefit per minute of activity is front-loaded**: The first 30 minutes of brisk walking per day (210 minutes/week) provides about 80% of the total mortality benefit. Adding another 30 minutes per day (to 420 minutes/week) provides only marginal additional benefit.

**Vigorous activity is about twice as efficient as moderate activity**: 10 minutes of jogging (vigorous) provides roughly the same mortality benefit as 20 minutes of brisk walking (moderate).

**Muscle strengthening twice per week** provides an additional 10–20% risk reduction on top of aerobic activity. This is roughly equivalent to adding an extra 50–100 minutes/week of moderate aerobic activity.

**Replacing 30 minutes of sitting with moderate activity** reduces mortality risk by approximately 15–20%. Replacing sitting with standing or light activity (e.g., slow walking) reduces risk by about 5–10%.

**For mental health**: The effect of exercise on depression (SMD ~0.40) is comparable to the effect of antidepressant medication (SMD ~0.30–0.50) or cognitive behavioural therapy (SMD ~0.50–0.70), though exercise has additional physical health benefits.

**For falls prevention**: A multicomponent exercise programme reduces fall risk by about 23%. This means if a typical older adult has a 30% chance of falling in a year, exercise reduces that to about 23%.

**What the authors acknowledge:**

The evidence base is dominated by observational studies (cohort, case-control), which cannot prove causation. Only a minority of outcomes (e.g., gestational weight gain, depression treatment) have strong RCT evidence.

Physical activity was mostly self-reported, which is subject to recall bias and social desirability bias. People tend to overestimate their activity by 30–50% compared to